| Today's News and Trends | Catecholaminergic polymorphic ventricular tachycardia is a rare, potentially fatal heart rhythm disorder. A new gene therapy candidate from Solid Biosciences is now one step closer to FDA approval. Catecholaminergic polymorphic ventricular tachycardia is a rare, potentially fatal heart rhythm disorder. A new gene therapy candidate from Solid Biosciences is now one step closer to FDA approval. | | |
| Cardiovascular-kidney-metabolic (CKM) syndrome is a popular research topic among cardiologists, highlighting just how closely obesity, type 2 diabetes, chronic kidney disease and cardiovascular disease are related to one another. Joshua Joseph, MD, spoke to Cardiovascular Business about this ongoing trend. Cardiovascular-kidney-metabolic (CKM) syndrome is a popular research topic among cardiologists, highlighting just how closely obesity, type 2 diabetes, chronic kidney disease and cardiovascular disease are related to one another. Joshua Joseph, MD, spoke to Cardiovascular Business about this ongoing trend. | | |
| Shockwave Medical, now a part of Johnson & Johnson MedTech, has consistently been found safe for patients. However, many previous clinical trials excluded high-risk patients, making it important to track real-world outcomes as time goes on. Shockwave Medical, now a part of Johnson & Johnson MedTech, has consistently been found safe for patients. However, many previous clinical trials excluded high-risk patients, making it important to track real-world outcomes as time goes on. | | |
| The FDA and other federal agencies believe limiting ultra-processed foods can help "Make America Healthy Again." They highlighted years of research linking these foods to increased risks of cardiovascular disease, type 2 diabetes and other conditions. The FDA and other federal agencies believe limiting ultra-processed foods can help "Make America Healthy Again." They highlighted years of research linking these foods to increased risks of cardiovascular disease, type 2 diabetes and other conditions. | | |
| | In fact, more than 55% of all PCI cases in 2022 were performed using radial access. Cardiologists are sure to be keeping a close eye on this trend as time goes on. In fact, more than 55% of all PCI cases in 2022 were performed using radial access. Cardiologists are sure to be keeping a close eye on this trend as time goes on. | | |
| The tricuspid valve has been at the center of several key policy shifts in recent years. In fact, Medicare now covers both T-TEER and TTVR when performed with FDA-approved devices. We spoke to interventional cardiologist Jason H. Rogers, MD, to learn more about how this momentum has impacted patient care. The tricuspid valve has been at the center of several key policy shifts in recent years. In fact, Medicare now covers both T-TEER and TTVR when performed with FDA-approved devices. We spoke to interventional cardiologist Jason H. Rogers, MD, to learn more about how this momentum has impacted patient care. | | |
| “This innovation was born out of necessity,” one surgeon explained. “We were determined to find a way to help the smallest and sickest children who previously had no access to DCD heart donation.” “This innovation was born out of necessity,” one surgeon explained. “We were determined to find a way to help the smallest and sickest children who previously had no access to DCD heart donation.” | | |
| | Researchers have been spending more and more time evaluating the Myval TAVR valve from Indian medtech company Meril Life Sciences. The balloon-expandable device is available in some parts of the world, but not the United States. Researchers have been spending more and more time evaluating the Myval TAVR valve from Indian medtech company Meril Life Sciences. The balloon-expandable device is available in some parts of the world, but not the United States. | | |
| The new guidelines detail the use of echocardiography to evaluate patients for a variety of conditions. The new guidelines detail the use of echocardiography to evaluate patients for a variety of conditions. | | |
| CMS has finalized a new national coverage determination for T-TEER, sometimes known as transcatheter tricuspid valve repair. Abbott's TriClip is the only device approved by the FDA for T-TEER, but other treatment options are under development. CMS has finalized a new national coverage determination for T-TEER, sometimes known as transcatheter tricuspid valve repair. Abbott's TriClip is the only device approved by the FDA for T-TEER, but other treatment options are under development. | | |
| | This boosts the New York-based vendor’s fundraising to $370 million since its founding in 2016, with the latest round including a $40 million revolving credit line. This boosts the New York-based vendor’s fundraising to $370 million since its founding in 2016, with the latest round including a $40 million revolving credit line. | | |
| In analyzing the impact of the One Big, Beautiful Bill Act, the nonpartisan Congressional Budget Office says Medicaid cuts and new work requirements will cause many Americans to lose their benefits. In analyzing the impact of the One Big, Beautiful Bill Act, the nonpartisan Congressional Budget Office says Medicaid cuts and new work requirements will cause many Americans to lose their benefits. | | |
| |
|
| ![]() | |
|
![The use of intravascular lithotripsy (IVL) during percutaneous coronary intervention (PCI) is still safe and effective when patients present with calcified nodules (CNs), according to new long-term data published in EuroIntervention.[1] Researchers compared outcomes from patients with and without CNs, highlighting key similarities in stent expansion and luminal gain.](https://cardiovascularbusiness.com/sites/default/files/styles/media_thumbnail/public/2024-12/screenshot_2024-12-02_at_11.07.21_am.png?itok=hecl3jAc)
